ArticleBMC cancer2018

Development of acquired resistance to lapatinib may sensitise HER2-positive breast cancer cells to apoptosis induction by obatoclax and TRAIL.

Alex J Eustace et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.